1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
ResMed Inc.

ResMed Inc.

RMD
ResMed Inc.US flagNew York Stock Exchange
221.89
USD
-0.41
- -
32.19BMarket Cap
ResMed Inc.
RMD
(New York Stock Exchange)

Recent

price

221.89

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
8.15
9.38
10.59
10.99
11.95
13.11
14.62
16.39
18.21
20.49
22
24.5
28.77
31.87
- -
- -
38.85
Revenue per Share
1.49
1.75
2.15
2.44
2.51
2.51
2.42
2.21
2.83
4.31
3.27
5.34
6.12
6.94
- -
- -
10.47
Basic EPS, GAAP
1.38
2.21
2.32
2.19
2.22
3.42
2.42
3.04
2.67
4.82
4.27
1.34
3.81
8.75
- -
- -
11.19
Free Cash Flow per Basic Share
- -
- -
0.68
1
1.12
1.2
1.32
1.4
1.48
1.56
1.56
1.68
1.76
1.92
- -
- -
2.4
Dividend per Share
11.41
11.32
11.34
12.53
11.3
12.05
13.79
14.43
14.42
17.23
19.81
22.95
28.08
33.11
40.77
45.66
45.66
Book Value per Share
9.54
9.13
9.06
10.15
9.08
2.39
4.46
5.43
-2.13
1.09
3.88
7.37
5.49
10.46
16.78
22.35
22.35
Tangible Book Value per Share
152
146
143
141
140
140
141
143
143
144
145
146
147
147
- -
- -
146
Basic Weighted Avg Shares
1,243
1,369
1,514
1,555
1,679
1,839
2,067
2,340
2,607
2,957
3,197
3,578
4,223
4,685
5,146
5,653
5,653
Sales/Revenue/Turnover
21.47
21.51
23.43
26.46
24.38
23.7
22.1
23.94
24.4
27.36
28.54
28.01
27.28
29.54
32.75
33.76
33.76
Operating Margin (%)
71
86
78
73
73
87
112
120
151
181
192
194
198
216
236
244
244
Depreciation Expense
227
255
307
345
353
352
342
316
405
622
475
779
898
1,021
1,401
1,523
1,523
Net Income, GAAP
25.26
23.23
20.25
19.9
19.05
19.83
18.26
39.46
22.02
15.2
46.3
18.85
18.53
19.28
16.5
20.64
20.64
Effective Tax Rate (%)
18.26
18.62
20.28
22.2
21.02
19.17
16.56
13.49
15.52
21.02
14.84
21.78
21.25
21.79
27.22
26.94
26.94
Profit Margin (%)
1,084
1,108
875
1,287
1,141
782
1,284
554
589
921
663
1,242
1,609
1,447
2,486
2,930
2,930
Working Capital
100
251
1
301
301
873
1,079
270
1,259
1,266
758
886
1,548
839
811
537
537
LT Debt
1,731
1,608
1,611
1,758
1,587
1,695
1,960
2,059
2,072
2,497
2,886
3,361
4,130
4,864
5,968
6,585
6,585
Total Equity
12.22
12.13
14.74
16.38
16.63
14.51
12.48
12.16
16.76
18.86
12.5
19.58
18.57
19.21
21.96
20.91
20.91
Return on Invested Capital (%)
14.09
14.01
16.56
17.64
18.12
15.2
12.37
12.37
15.23
18.37
13.04
20.04
18.75
18.48
22.31
21.41
21.41
Return on Capital (%)
15.04
15.27
19.09
20.5
21.1
21.47
18.73
15.7
19.59
27.21
17.63
24.96
23.96
22.7
25.86
24.27
24.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
290
289
289
LT Borrowings
404
404
399
LT Finance Leases
154
150
137
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
146
145
144
Market Capitalization
35,086
32,559
28,109

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
3,819
4,064
4,325
Cash, Cash Equivalents & STI
1,417
1,661
1,469
Accounts Receivable, Net
986
999
1,036
Inventories
922
912
946
Total Current Liabilities
1,248
1,351
1,395
Payables & Accruals
782
883
885
ST Debt
290
289
289
Deferred Revenue
176
179
163

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.76%
18.03%
10.35%
Free Cash Flow
33.25%
55.02%
-1.35%
Net Income, GAAP
18.66%
27.82%
8.75%
Sales/Revenue/Turnover
11.92%
12.12%
9.85%
Total Cash Common Dividend
7.64%
9.08%
12.47%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,102
1,163
1,197
1,223
4,685
2025
1,225
1,282
1,292
1,348
5,146
2026
1,336
1,423
1,431
1,464
5,653

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.49
1.42
2.04
1.99
6.94
2025
2.12
2.35
2.49
2.59
- -
2026
2.38
2.69
2.74
2.65
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.48
0.48
0.48
0.48
1.92
2025
0.53
0.53
0.53
0.53
- -
2026
0.6
0.6
0.6
0.6
- -
Similar Companies
Opsens Inc. (OPSSF)
Tecan Group AG (TECN.SW)
COLTENE Holding AG (CLHLF)
Zhejiang Gongdong Medical Technology Co.,Ltd. (605369.SS)
Femasys Inc. (FEMY)
Coloplast A/S (CLPBF)
Business
ResMed Inc. (NYSE: RMD; ASX: RMD) develops, manufactures, distributes and markets cloud-connected medical devices, digital health technologies and software platforms that diagnose, treat and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), respiratory insufficiency and other chronic diseases. The company offers continuous positive airway pressure (CPAP) and automatic positive airway pressure (APAP) devices including the AirSense and Air11 series; masks and accessories such as the AirFit, AirTouch N30i and F30i fabric-based platforms; ventilators like the Lumis series for non-invasive support; humidifiers including HumidCare; portable options such as AirMini; and software solutions encompassing myAir for patient self-monitoring, AirView for remote clinician oversight, and SaaS platforms for out-of-hospital care providers including residential care management tools. It operates through two primary segments: Sleep and Respiratory Care, addressing obstructive sleep apnea, central sleep apnea, overlap syndrome, obesity hypoventilation and neuromuscular diseases; and Software as a Service (SaaS), supporting healthcare professionals with data-driven platforms. ResMed serves patients, clinicians, sleep labs, homecare providers and health systems in over 140 countries, with key growth markets in the United States, Canada, Latin America, Europe, China, South Korea, India, Brazil and Eastern Europe. Founded in 1989 by Dr. Peter Farrell in Sydney, Australia, to commercialize CPAP technology, the company is headquartered in San Diego, California, and employs approximately 10,600 people. Recent developments include the May 2025 acquisition of VirtuOx, a leading independent diagnostic testing facility for at-home sleep, respiratory and cardiac testing, which operates as a wholly owned subsidiary to streamline diagnostics, enhance virtual care coordination and expand into adjacent areas like insomnia; launches of new AirTouch F30i mask variants including the comfort edition in Australia and clear edition in the U.S.; strategic U.S. manufacturing and distribution expansion in Indianapolis; and a board leadership change with director Richard Sulpizio departing following the 2025 annual stockholders' meeting.

Company News

Company News APIChatGPT

  • defenseworld.net

    ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

  • marketbeat.com

    ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

  • defenseworld.net

    Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD

  • barrons.com

    Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

  • seekingalpha.com

    Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'

  • seekingalpha.com

    ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • zacks.com

    Is This the Right Time to Retain Resmed Stock in Your Portfolio?

  • 247wallst.com

    Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More

  • seekingalpha.com

    ResMed: A Significant Upside Despite The Perceived Risk

  • 247wallst.com

    The IRS Lets You Send Your RMD Straight to Charity and Skip the Tax Entirely. These 3 ETFs Replace the Income You Gave Away

  • defenseworld.net

    ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • defenseworld.net

    Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • globenewswire.com

    Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

  • defenseworld.net

    228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • 247wallst.com

    The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a Share

  • globenewswire.com

    Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor